Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
CAMBRIDGE, Mass., May 04, 2017 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:
| What: | Vericel Corporation First-Quarter 2017 Earnings Call | ||||
| When: | Wednesday, May 10, 2017 at 8:00am (ET) | ||||
| Where: | http://investors.vcel.com/events.cfm | ||||
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. | ||||
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation first-quarter 2017 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until May 10, 2018. A replay of the call will also be available until 11:00 am (ET) on May 14, 2017 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 11385924.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
